Results 291 to 300 of about 6,088,045 (339)

Public perceptions of high-cost cancer drugs and the implications for reimbursement decisions. [PDF]

Health Econ Rev
Noh Y, Son KB.
europepmc   +1 more source

The Diagnostic Value of Visual Evoked Potentials in Chronic Disorders of Consciousness

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective In chronic disorders of consciousness (DOCs), the distinction between vegetative state/unresponsive wakefulness syndrome (VS/UWS) and minimally conscious state (MCS) is as crucial as it is challenging. Evoked potentials (EPs) and event‐related potentials (ERPs) are helpful, but some limitations prevent their consistent use in the ...
Letizia Clementi, Francesca Giulia Magnani, Filippo Barbadoro, Camilla Ippoliti, Martina Cacciatore, Davide Sattin, Valeria Pingue, Benedetta Cazzulani, Jorge Navarro, Elena Schiaffi, Laura Grigoletti, Cristina Rosazza, Anna Nigri, Matilde Leonardi, Davide Rossi Sebastiano   +14 more
wiley   +1 more source

Using Dose-Escalation and -Expansion Cohort Study as Pivotal Trial for Targeted Anticancer Drug Approval. [PDF]

JCO Precis Oncol
Huang Y, Zhu T, Zhong J, Yuan J.
europepmc   +1 more source

BCS1L‐Associated Disease: 5′‐UTR Variant Shifts the Phenotype Towards Axonal Neuropathy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives To investigate the consequences of a pathogenic missense variant (c.838C>T; p.L280F) and a 5′‐UTR regulatory variant (c.‐122G>T) in BCS1L on disease pathogenesis and to understand how regulatory variants influence disease severity and clinical presentation.
Rotem Orbach, Nunziata Maio, Russell J. Butterfield, A. Reghan Foley, Sarah Silverstein, Yan Li, Katherine Chao, Tanya J. Lehky, Abigail Potticary, Tracey A. Rouault, Sandra Donkervoort, Carsten G. Bönnemann   +11 more
wiley   +1 more source

Research and development investments for biologics independently developed by US biotechnology startups, 2017-2023. [PDF]

Health Aff Sch
Odouard IC, Kang SY, Mo J, Anderson GF, Alexander GC.   +4 more
europepmc   +1 more source

Performance of Composite Endpoints Defining Progression Independent of Relapse Activity in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The characteristics and utility of composite progression independent of relapse activity (cPIRA; worsening on the Expanded Disability Status Scale [EDSS], or 9‐Hole Peg Test, or Timed 25‐Foot Walk Test) were evaluated as an endpoint in relapsing multiple sclerosis (RMS) trials using the ENSEMBLE (NCT03085810) and pooled OPERA I/II ...
Ludwig Kappos, Sean Yiu, Jason Reucassel, Jiwon Oh, Cristina Granziera, Joep Killestein, Robert A. Bermel, Claude Berge, Agne Kazlauskaite, Hans‐Martin Schneble, Frank Dahlke, Bruce A. C. Cree   +11 more
wiley   +1 more source

Estimating the Population Size of People Who Inject Drugs in 3 Cities in Zambia: Capture-Recapture, Successive Sampling, and Bayesian Consensus Estimation Methods.

JMIR Public Health Surveill
Parmley L, Reid G, Neal JJ, Hanunka B, Tally L, Chilukutu L, Nkumbula T, Mulemfwe C, Chelu L, Handema R, Mwale J, Mutale K, Mulenga L, McIntyre AF, Philip NM, Chung H, Lahuerta M.   +16 more
europepmc   +1 more source

Recent Research Advances in HER2-Positive Breast Cancer Concerning Targeted Therapy Drugs. [PDF]

Molecules
Li J, Li X, Fu R, Fang Y, Zhang C, Ma B, Ding Y, Shi C, Zhou Q.   +8 more
europepmc   +1 more source

InterPAD is a database of drug-drug interaction between phytochemicals and anticancer drugs. [PDF]

Sci Rep
Zhang A, Sun X, Wu Q, Jiang H, Xu L, Gao Q, Yang Z, Zhu S, Sui X.   +8 more
europepmc   +1 more source